Skip to main content
All targets are shown
Gene
Drug Category
Drug Class
Download CSV
Gene NCT ID Antigen/Ligand Binding Type Drug Name Drug Type Drug NCI Concept Drug Category Drug Class Drug Description Drug Mechanism of Action Cytotoxicity Cytotoxicity Type Target Cytotoxicity Mechanism Disease Disease Type Tissue OncoTree Main Type OncoTree Name Annotation Status
CD8A NCT05902416 CD8 alpha antigen recognition Anti-thymocyte globulin RELEVANT_DRUG CYTOTOXIC ANTIBODY Cytotoxic protein Polyclonal antibody that depletes T cells to reduce rejection and GVHD. Polyclonal anti–T-cell IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, producing immunosuppression to reduce rejection and GVHD. YES DIRECT Polyclonal antibodies bind CD8α on T cells and trigger complement-dependent lysis and Fc-mediated ADCC/phagocytosis, depleting CD8+ cells. Myelodysplastic Syndromes CANCER Myeloid Myelodysplastic Syndromes Myelodysplastic Syndromes ai
CD5 NCT05902416 CD5 antigen recognition Anti-thymocyte globulin RELEVANT_DRUG CYTOTOXIC ANTIBODY Cytotoxic protein Polyclonal antibody that depletes T cells to reduce rejection and GVHD. Polyclonal anti–T-cell IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, producing immunosuppression to reduce rejection and GVHD. YES DIRECT Polyclonal IgG in ATG binds CD5 on T cells and triggers complement-dependent lysis and Fc receptor–mediated ADCC/phagocytosis, depleting the bound cells. Myelodysplastic Syndromes CANCER Myeloid Myelodysplastic Syndromes Myelodysplastic Syndromes ai
CD7 NCT05902416 CD7 antigen recognition Anti-thymocyte globulin RELEVANT_DRUG CYTOTOXIC ANTIBODY Cytotoxic protein Polyclonal antibody that depletes T cells to reduce rejection and GVHD. Polyclonal anti–T-cell IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, producing immunosuppression to reduce rejection and GVHD. YES DIRECT Polyclonal antibodies in ATG bind CD7 (among other T‑cell antigens) and induce complement-dependent lysis and Fc-mediated ADCC/phagocytosis, depleting CD7+ T cells. Myelodysplastic Syndromes CANCER Myeloid Myelodysplastic Syndromes Myelodysplastic Syndromes ai
IL2RA NCT05902416 CD25 (IL-2 receptor alpha) antigen recognition Anti-thymocyte globulin RELEVANT_DRUG CYTOTOXIC ANTIBODY Cytotoxic protein Polyclonal antibody that depletes T cells to reduce rejection and GVHD. Polyclonal anti–T-cell IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, producing immunosuppression to reduce rejection and GVHD. YES DIRECT Polyclonal antibodies in ATG bind CD25 (and other T‑cell antigens) on T cells, triggering complement-dependent lysis and Fc-mediated ADCC/phagocytosis to deplete CD25+ T cells. Myelodysplastic Syndromes CANCER Myeloid Myelodysplastic Syndromes Myelodysplastic Syndromes ai
CD28 NCT05902416 CD28 antigen recognition Anti-thymocyte globulin RELEVANT_DRUG CYTOTOXIC ANTIBODY Cytotoxic protein Polyclonal antibody that depletes T cells to reduce rejection and GVHD. Polyclonal anti–T-cell IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, producing immunosuppression to reduce rejection and GVHD. YES DIRECT Anti-thymocyte globulin binds CD28 on T cells; its Fc activates complement and engages Fcγ-expressing effectors to mediate complement-dependent lysis and ADCC/ADCP, depleting CD28+ cells. Myelodysplastic Syndromes CANCER Myeloid Myelodysplastic Syndromes Myelodysplastic Syndromes ai
Displaying 1611 - 1615 of 5381